Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation
Advanced Science · 2026-11 · 13 (62)
DOI: 10.1002/advs.76992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 19.08.2026. Verfasst von Qingyang Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanji…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Homeodomain Proteins, Calcium-Calmodulin-Dependent Protein Kinase Type 2. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation, Basic Research Program of Jiangsu Province, Jiangsu Province Capability Improvement Project.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer mortality, and the molecular drivers of progression and distant metastasis are incompletely understood. By integrating differential expression and survival analyses of TCGA CRC cohorts with HOX family genes, we identified HOXC11 as a key metastasis‐associated factor. HOXC11 was markedly upregulated in CRC tissues and cell lines, with higher expression in metastatic lesions than in primary tumors, and elevated HOXC11 correlated with poor patient prognosis. HOXC11 functionally increased CRC cell proliferation, migration, and invasion in vitro and facilitated tumor growth and metastasis in vivo. Mechanistically, HOXC11 directly bound to the CAMK2A promoter and transactivated CAMK2A, leading to increased phosphorylated CAMK2A and initiation of the NF‐κB pathway, which facilitated p65 nuclear translocation and induced CXCL5 expression to drive CRC progression. Conversely, CXCL5 signaling through CXCR2 upregulated HOXC11 via the ERK1/2‐SP1 axis, forming a positive feedback loop. Notably, combined inhibition of CAMK2A (KN‐93) and CXCR2 (SB265610) significantly attenuated HOXC11‐mediated proliferation and metastasis. Collectively, these findings define a HOXC11–CAMK2A–NF‐κB–CXCL5 circuit as a potential therapeutic target in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
- The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, China.
- Department of General Surgery, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China.
- Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China.
ORCID-Profile: Hengjie Xu, Sheng Yang, Jiahui Zhou, Xiaowei Wang, Yueming Sun
Förderung
- National Natural Science Foundation
- Basic Research Program of Jiangsu Province
- Jiangsu Province Capability Improvement Project
Zitieren
APA
Sun, Q., Xu, H., Yang, S., Zhou, J., Tian, C., Nie, H., Jin, C., Wang, T., Chen, Z., Tang, J., Feng, Y., Wang, X., & Sun, Y. (2026). Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation. Advanced Science, 13(62). https://doi.org/10.1002/advs.76992
Vancouver
Sun Q, Xu H, Yang S, Zhou J, Tian C, Nie H, et al. Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation. Advanced Science. 2026;13(62). doi:10.1002/advs.76992
BibTeX
@article{Sun2026,
author = {Sun, Qingyang and Xu, Hengjie and Yang, Sheng and Zhou, Jiahui and Tian, Chuanxin and Nie, Hongxu and Jin, Chi and Wang, Tuo and Chen, Zhihao and Tang, Junwei and Feng, Yifei and Wang, Xiaowei and Sun, Yueming},
title = {Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {62},
doi = {10.1002/advs.76992}
}
EUVIMED